Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis. — SALTEA GABAbr  

Autoimmune Encephalitis Clinical Trial

Official title: Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis.

Status Completed

Clinical Trial Summary

First described in 2010, GABA-B-receptor antibodies-associated encephalitis is a disease with a severe vital and functional prognosis. Indeed, functional status is mostly altered by encephalitis and it induced consequences while vital status is mostly engaged by cancer very often associated in the course of the disease, mostly small-cell lung cancer (SCLC). While knowledge is growing on clinical features at each stage of the disease, long-term outcome data is still lacking even if known to be pejorative. In this study, we aimed to describe long-term follow up of all patients who were diagnosed a GABAb-receptor antibodies-associated encephalitis in the French Paraneoplastic Neurological Syndrome Reference Center until now.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Autoimmune Encephalitis
• Encephalitis

• NCT number: NCT05741619
• Study type: Observational
• Source: Hospices Civils de Lyon
• Status: Completed
• Start date: January 1, 2022
• Completion date: September 1, 2022